Business Overview: Spruce Biosciences, Inc. (NASDAQ: SPRB)

---

Executive Summary

Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in April 2016. The company develops therapies for serious, biologically well-understood diseases that currently have no approved treatment or only suboptimal options — a strategy it pursues with a lean team of just 8 full-time employees. Spruce's lead program is TA-ERT (tralesinidase alfa), an enzyme replacement therapy delivered directly into the cerebrospinal fluid to treat MPS IIIB (Sanfilippo Syndrome Type B), an ultra-rare, fatal pediatric neurodegenerative disease with a mean life expectancy of roughly 19 years and zero FDA-approved therapies today.

Spruce matters not because of its current size — it is a micro-cap company that spent part of 2025 trading on the OTCQB before Nasdaq approved its return to the Nasdaq Capital Market in September 2025 — but because it is one of a small number of companies positioned to bring the first-ever approved treatment to market for a devastating, 100%-fatal rare pediatric disease, via an accelerated-approval pathway the FDA has already signaled support for. A second pipeline asset, SPR202 for congenital adrenal hyperplasia (CAH), gives the company a shot at a second, larger indication, though it now competes against an already-approved rival drug.

The company's history is itself notable: TA-ERT was originally developed by BioMarin, licensed out to Allievex Corporation, and then reacquired by Spruce in October 2024 out of Allievex's bankruptcy estate — meaning Spruce picked up a clinically de-risked, late-stage asset at a fraction of its original development cost.

---

1. Core Business Model & How They Work

Spruce does not generate product revenue today. Its business model is the standard clinical-stage biopharma playbook: in-license or acquire promising but underfunded/orphaned drug candidates, run the remaining clinical and regulatory work needed for approval, and plan to commercialize directly (for an ultra-rare, high-touch CNS disease) or via partnership once approved. Value is created by advancing assets through FDA milestones (Breakthrough Therapy and Fast Track designations, Type B meetings, BLA filing) that both de-risk the program and make it attractive for financing, partnership, or acquisition.

 In-license / acquire a          Run confirmatory trials      File BLA, pursue
 clinically-derisked asset   ➡️  & FDA meetings (Type B,   ➡️  accelerated approval
 (e.g., TA-ERT from              Breakthrough Therapy,          (surrogate endpoint:
 BioMarin/Allievex estate;       Fast Track, Orphan Drug)        CSF heparan sulfate
 SPR202 from HBM Alpha)                                          reduction)
        │                                                              │
        │                                                              ▼
        │                                               Commercialize in ultra-rare
        │                                               disease (premium orphan
        │                                               pricing, voucher monetization,
        │                                               small dedicated sales/CNS
        │                                               infusion network) OR partner/
        │                                               license post-approval
        ▼
 Fund operations via equity
 raises, milestone-based
 licensing (royalties owed
 to BioMarin/Eli Lilly/HBM),
 and debt (Avenue Capital
 loan facility, up to $50M)

Because MPS IIIB is ultra-rare, Spruce is also eligible for a Rare Pediatric Disease Priority Review Voucher if TA-ERT is approved — vouchers of this type have historically sold for $100M+ and represent a monetizable, non-dilutive value driver independent of the drug's own commercial performance.

---

2. Pipeline

Given that essentially all current R&D investment and forward-looking value is concentrated in a single therapeutic approach (rare-disease enzyme/antibody replacement, administered by a small specialized team), Spruce operates as a single-segment business; a standalone "Business Segments" breakdown is not meaningful here.

---

3. Competitive Landscape

MPS IIIB / Sanfilippo Syndrome (TA-ERT): The ultra-rare disease space has historically drawn gene-therapy approaches rather than enzyme replacement. Ultragenyx Pharmaceutical holds rights to gene therapy assets for Sanfilippo syndrome (having acquired Abeona Therapeutics' related program), and earlier efforts by companies such as Lysogene targeted similar biology with mixed clinical results. Spruce's ERT approach (repeated ICV infusion) differs mechanistically from one-time gene therapy, giving it a differentiated, if less convenient, modality — and it is the only ERT candidate with an active, FDA-aligned accelerated-approval path specifically for MPS IIIB (Type B), versus competitors more focused on Type A disease.

Congenital Adrenal Hyperplasia (SPR202): This field changed materially in December 2024 when Neurocrine Biosciences' crinecerfont (brand name Crenessity) became the first FDA-approved non-glucocorticoid treatment for classic CAH — a much larger, commercial-stage, well-funded competitor. SPR202 (and the now-discontinued tildacerfont) must differentiate on mechanism, dosing, or a sub-population Crenessity doesn't fully address; Spruce enters this market from a position of clear scale disadvantage.

                High unmet need / no approved therapy
                              ▲
                              │
            TA-ERT (Spruce) ●│
                              │
                              │         ● Gene therapy competitors
                              │           (Ultragenyx, ex-Abeona assets)
   Niche, ultra-rare ◀────────┼────────▶ Broader, larger patient population
   small population            │
                              │   ● SPR202 (Spruce)
                              │
                              │                    ● Crenessity (Neurocrine,
                              │                      FDA-approved, commercial)
                              ▼
                High unmet need / no approved therapy

---

4. Strategic Strengths & Risks

Strengths:

• First-mover / only-mover potential in MPS IIIB: No FDA-approved therapy exists for this disease, and the FDA has already signaled a viable accelerated-approval path using a surrogate biomarker, materially de-risking the regulatory outcome versus a typical first-in-class rare-disease program.
• Clinically advanced, acquired cheaply: TA-ERT was developed and clinically tested for years under BioMarin before Spruce acquired it out of Allievex's bankruptcy estate in October 2024 — Spruce effectively bought years of clinical data and FDA engagement at a fraction of ground-up development cost.
• Regulatory designations stack: Rare Pediatric Disease, Fast Track, Breakthrough Therapy, and Orphan Drug designations (US and EU) for TA-ERT reduce review risk and extend exclusivity runway, and make the program eligible for a monetizable Priority Review Voucher.
• Lean cost structure: Only 8 employees and reliance on contract manufacturers keeps fixed costs low relative to the value of the pipeline, extending runway per dollar raised.

Risks:

• Explicit going-concern doubt: Spruce's own FY2025 10-K states it does "not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern," even though the company separately guides that current cash funds operations "into early 2027" — the gap reflects that $35M of its new $50M Avenue Capital loan facility is conditional and not guaranteed to fund.
• No approved products, no product revenue: All near-term value depends on a single BLA filing (TA-ERT, targeted Q4 2026) succeeding on an accelerated, surrogate-endpoint basis that the FDA could still revisit.
• Pipeline attrition already visible: Two programs (tildacerfont for CAH, and tildacerfont/Cortibon for MDD) were discontinued in 2025-2026, the latter after a serious liver-related adverse event — a reminder that clinical risk is real and recent.
• Thin trading history / small float: The stock moved between OTCQB and Nasdaq Capital Market within 2025, and non-affiliate market value was only about $2.8 million as of mid-2025 — a signal of extreme size and liquidity risk typical of distressed-to-recovering micro-cap biotech.
• Heavy royalty/milestone obligations: Spruce owes layered milestones and royalties to BioMarin (TA-ERT), Eli Lilly (tildacerfont-related IP), and HBM Alpha (SPR202), which will compress economics even if products reach market.

---

5. Financial Overview

---

6. Summary Conclusion

Spruce Biosciences is a focused, single-asset-driven clinical-stage biotech whose entire near-term investment case rests on TA-ERT reaching an accelerated FDA approval for MPS IIIB in a market with no existing treatment — a genuine, if narrow, moat built on regulatory designations, a biologically validated mechanism, and years of pre-existing clinical data acquired cheaply out of a predecessor's bankruptcy. SPR202 offers a secondary shot at the larger CAH market, but it now trails an already-approved competitor. The company's single biggest forward risk is financial, not scientific: its own 10-K discloses explicit going-concern doubt, its remaining debt financing is only partly committed, and its cash runway is tightly sized around the Q4 2026 BLA filing — meaning execution risk and financing risk are now as material to the stock as the clinical and regulatory risk around TA-ERT itself.